nafld and glutathione

nafld and glutathione disulfide sensitizes hepatocytes to TNFα-mediated cytotoxicity via IKK-β S-glutathionylation: a potential mechanism underlying non-alcoholic fatty liver disease Toxins to treatments: Impact of

Name: nafld and glutathione disulfide sensitizes hepatocytes to TNFα-mediated cytotoxicity via IKK-β S-glutathionylation: a potential mechanism underlying non-alcoholic fatty liver disease Toxins to treatments: Impact of
Brand: condeoeiras.edu.pt
SKU: 62010153893
Price: 26.75 USD
Availability: InStock
Rating: 4.6930000000000005 (13 reviews)

Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non alcoholic fatty liver disease progression PMC A Western diet induced NAFLD in LDLR mice is associated with reduced hepatic glutathione synthesis ScienceDirect glutathione for nafld liposomal nonalcoholic fatty liver disease Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery Glutathione disulfide sensitizes hepatocytes to A brief comparison of NAFLD NASH prevention and therapy between Download Scientific Diagram glutathione nafld Multi omic profiles of human non alcoholic fatty liver disease tissue highlight heterogenic phenotypes An overview of ferroptosis in Inflammatory responses induction in NAFLD NASH. Abbreviation: GPx, Download Scientific Diagram

SKU: 62010153893 · From condeoeiras.edu.pt

4.7

USD26.75 USD46.75

Pay in 4 interest-free payments of $6.69 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 30 - Aug 4

Description

Oteiza, Marcela A

nafld and glutathione disulfide sensitizes hepatocytes to TNF-mediated cytotoxicity via IKK- S-glutathionylation: a potential mechanism underlying non-alcoholic fatty liver disease Toxins to treatments: Impact of

Adelson, E

doi:10.1016/j.idc.2009.10.002

Glutamine and glutamate in mammals, Vol

Summary Glutathione is a key antioxidant made by our bodies

3.5 Subgroup analysis To address the considerable heterogeneity observed across studies, we performed subgroup analyses focusing on three confounding factors (animal species, treatment agents, model drugs and dosages), to identify the sources of heterogeneity for the five primary outcomes (AST, ALT, SOD, MDA, GSH)